CS131891A3 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
CS131891A3
CS131891A3 CS911318A CS131891A CS131891A3 CS 131891 A3 CS131891 A3 CS 131891A3 CS 911318 A CS911318 A CS 911318A CS 131891 A CS131891 A CS 131891A CS 131891 A3 CS131891 A3 CS 131891A3
Authority
CS
Czechoslovakia
Prior art keywords
group
composition
amino acid
polypeptide
composition according
Prior art date
Application number
CS911318A
Other languages
Czech (cs)
English (en)
Inventor
Christopher L Penny
Original Assignee
North American Vaccine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine filed Critical North American Vaccine
Publication of CS131891A3 publication Critical patent/CS131891A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CS911318A 1990-05-07 1991-05-06 Vaccine CS131891A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51846090A 1990-05-07 1990-05-07

Publications (1)

Publication Number Publication Date
CS131891A3 true CS131891A3 (en) 1992-02-19

Family

ID=24064028

Family Applications (1)

Application Number Title Priority Date Filing Date
CS911318A CS131891A3 (en) 1990-05-07 1991-05-06 Vaccine

Country Status (22)

Country Link
EP (1) EP0597838B1 (de)
JP (1) JPH05506234A (de)
CN (1) CN1056816A (de)
AT (1) ATE173936T1 (de)
AU (1) AU7777991A (de)
CA (1) CA2082425A1 (de)
CS (1) CS131891A3 (de)
DE (1) DE69130576T2 (de)
DK (1) DK0597838T3 (de)
ES (1) ES2124701T3 (de)
FI (1) FI925032A0 (de)
HR (1) HRP930658A2 (de)
HU (1) HUT65493A (de)
IE (1) IE911527A1 (de)
IL (1) IL97985A0 (de)
MX (1) MX172210B (de)
NO (1) NO924271L (de)
NZ (1) NZ238042A (de)
TW (1) TW221676B (de)
WO (1) WO1991016926A1 (de)
YU (1) YU79691A (de)
ZA (1) ZA913214B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2006502213A (ja) * 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 George Wojcik Synthetic adjuvants for stimulation of antigenic responses
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen

Also Published As

Publication number Publication date
EP0597838A1 (de) 1994-05-25
HRP930658A2 (en) 1997-12-31
HU9203480D0 (en) 1993-01-28
NO924271D0 (no) 1992-11-06
MX172210B (es) 1993-12-07
TW221676B (de) 1994-03-11
FI925032A (fi) 1992-11-06
IE911527A1 (en) 1991-11-20
DK0597838T3 (da) 1999-08-16
EP0597838B1 (de) 1998-12-02
NZ238042A (en) 1993-12-23
DE69130576D1 (de) 1999-01-14
CN1056816A (zh) 1991-12-11
ZA913214B (en) 1992-09-30
ATE173936T1 (de) 1998-12-15
JPH05506234A (ja) 1993-09-16
NO924271L (no) 1993-01-07
AU7777991A (en) 1991-11-27
WO1991016926A1 (en) 1991-11-14
YU79691A (sh) 1994-06-10
IL97985A0 (en) 1992-06-21
CA2082425A1 (en) 1991-11-08
FI925032A0 (fi) 1992-11-06
ES2124701T3 (es) 1999-02-16
DE69130576T2 (de) 1999-07-29
HUT65493A (en) 1994-06-28

Similar Documents

Publication Publication Date Title
KR100290632B1 (ko) 면역성이약한항원공액체와이를포함하는합성펩티드담체와백신
CA1329766C (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
US5837250A (en) Adjuvant compositions
JP4031201B2 (ja) アレルギー治療用免疫原としてのペプチド組成物
CA2793087C (en) Peptides, conjugates and method for increasing immunogenicity of a vaccine
CS283991A3 (en) Vaccine
US6403092B1 (en) Immune response modulator alpha-2 macroglobulin complex
JPH09510975A (ja) アレルギー治療用合成ペプチドベース免疫原
KR102077876B1 (ko) Crm197 담체 단백질에 커플링된 hiv gp41 펩티드를 포함하는 면역원성 화합물
CS131891A3 (en) Vaccine
US4919930A (en) Synthetic M proteins-streptococci type 5
Robinson et al. Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells.
KR20220062080A (ko) 전립선암 치료를 위한 면역요법
US6290971B1 (en) Adjuvant compositions comprising a mineral salt and another immunostimulating compound
AU754988B2 (en) Immune response modulator alpha-2 macroglobulin complex
HUT71776A (en) Antibody conjugates with improved properties
EP0674907A2 (de) Antikörper-Trägerprotein-Konjugate, zur Verwendung bei der aktiven Immunotherapie